A study of MRI-guided diffuse fluorescence molecular tomography for monitoring PDT effects in pancreas cancer

Kimberley S. Samkoe; Scott C. Davis; Subhadra Srinivasan; Julia A. O'Hara; Tayyaba Hasan; Brian W. Pogue

doi:10.1117/12.823079

13 July 2009 A study of MRI-guided diffuse fluorescence molecular tomography for monitoring PDT effects in pancreas cancer

Kimberley S. Samkoe, Scott C. Davis, Subhadra Srinivasan, Julia A. O'Hara, Tayyaba Hasan, Brian W. Pogue

Author Affiliations +

Proceedings Volume 7380, Photodynamic Therapy: Back to the Future; 73803M (2009) https://doi.org/10.1117/12.823079
Event: 12th World Congress of the International Photodynamic Association, 2009, Seattle, Washington, United States

Abstract

Over the last several decades little progress has been made in the therapy and treatment monitoring of pancreas adenocarcinoma, a devastating and aggressive form of cancer that has a 5-year patient survival rate of 3%. Currently, investigations for the use of interstitial Verteporfin photodynamic therapy (PDT) are being undertaken in both orthotopic xenograft mouse models and in human clinical trials. In the mouse models, magnetic resonance (MR) imaging has been used as a measure of surrogate response to Verteporfin PDT; however, MR imaging alone lacks the molecular information required to assess the metabolic function and growth rates of the tumor immediately after treatment. We propose the implementation of MR-guided fluorescence tomography in conjunction with a fluorescently labeled (IR-Dye 800 CW, LI-COR) epidermal growth factor (EGF) as a molecular measure of surrogate response. To demonstrate the effectiveness of MR-guided diffuse fluorescence tomography for molecular imaging, we have used the AsPC-1 (+EGFR) human pancreatic adenocarcinoma in an orthotopic mouse model. EGF IRDye 800CW was injected 48 hours prior to imaging. MR image sequences were collected simultaneously with the fluorescence data using a MR-coupled diffuse optical tomography system. Image reconstruction was performed multiple times with varying abdominal organ segmentation in order to obtain a optimal tomographic image. It is shown that diffuse fluorescence tomography of the orthotopic pancreas model is feasible, with consideration of confounding fluorescence signals from the multiple organs and tissues surrounding the pancreas. MR-guided diffuse fluorescence tomography will be used to monitor EGF response after photodynamic therapy. Additionally, it provide the opportunity to individualize subsequent therapies based on response to PDT as well as to evaluate the success of combination therapies, such as PDT with chemotherapy, antibody therapy or even radiation.

Citation Download Citation

Kimberley S. Samkoe, Scott C. Davis, Subhadra Srinivasan, Julia A. O'Hara, Tayyaba Hasan, and Brian W. Pogue "A study of MRI-guided diffuse fluorescence molecular tomography for monitoring PDT effects in pancreas cancer", Proc. SPIE 7380, Photodynamic Therapy: Back to the Future, 73803M (13 July 2009); https://doi.org/10.1117/12.823079

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available